There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > SOST


SOST Molecule Information

Target Synonym:SOST;Sclerostin
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Approved

SOST Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
Cat. No. Species Product Description Structure Purity Feature
SOT-H8245 Human Biotinylated Human SOST / Sclerostin Protein, His Tag, ultra sensitivity (primary amine labeling)
HST-H5245 Human Human SOST / Sclerostin Protein, His Tag

SOST Part of Bioactivity data

Human SOST, His TagHuman SOST, His Tag (Cat. No. HST-H5245) ELISA bioactivity

Immobilized Human SOST, His Tag (Cat. No. HST-H5245) at 5 μg/mL (100 μL/well) can bind Human LRP-6 (20-630), Mouse IgG2a Fc Tag (Cat. No. LR6-H5253) with a linear range of 10-78 ng/mL (QC tested).

SOST Molecule Synonym Name


SOST Molecule Background

Sclerostin (SOST) is also known as Sclerosteosis, VBCH, is a secreted glycoprotein with a signal peptide for secretion and a C-terminal cysteine knot-like (CTCK) domain and belongs to the Cerberus/DAN family of bone morphogenetic protein (BMP) antagonists. Sclerostin is produced by the osteocyte and has anti-anabolic effects on bone formation. More recently Sclerostin has been identified as binding to LRP5/6 receptors and inhibiting the Wnt signalling pathway. Wnt pathway inhibition under these circumstances is antagonistic to bone formation (meaning Sclerostin antagonizes bone formation). It has been shown that SOST binds BMP-5, -6, and -7 with high affinity and BMP-2 and -4 with low affinity. Sclerostin production by osteocytes is inhibited by parathyroid hormone, mechanical loading and cytokines including oncostatin M, cardiotrophin-1 and leukemia inhibitory factor. Sclerostin production is increased by calcitonin. Thus, osteoblast activity is self regulated by a negative feedback system. Mutations of Sclerostin is associated with the syndrome Sclerosteosis, and reduced sclerostin expression results in a milder form of the disorder called van Buchem disease.

SOST References

SOST Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Romosozumab AMG-785; CDP-7851,AMG785,CDP7851 Approved Amgen, UCB, Astellas Romosozumab 日本 Osteoporosis 安斯泰来,安进,优时比 2019-01-08 00:00:00.0 Osteoporosis Details

SOST Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
AMG-167 AMG-167 Phase Ⅰ Amgen Osteoporosis Details
Setrusumab BPS-804; MOR-05813; NOV-3 Phase Ⅱ MorphoSys, Novartis, Mereo BioPharma Osteogenesis imperfecta Details
Blosozumab LY-2541546,LY2541546 Phase Ⅱ Lilly Osteoporosis Details
SHR-1222 SHR-1222 Phase Ⅰ Jiangsu Hengrui Medicine, Shanghai Hengrui, Suzhou Shengdiya Osteoporosis Details

This web search service is supported by Google Inc.